Skip to main content

Table 2 Predictors of TD. Univariable and multivariable Cox regression

From: Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Variables HR (95% CI) p aHR (95% CI) p
Age (per 10 years more) 1.03 (0.91–1.15) 0.675 1.04 (0.91–1.19) 0.565
HIV risk factor:
 Heteosexual Ref   Ref  
 MSM 1.14 (0.87–1.50) 0.358 1.25 (0.93–1.68) 0.143
 IDUs 1.39 (0.93–2.08) 0.112 1.75 (1.13–2.70) 0.011
 Other 1.72 (0.24–12.38) 0.590 0.84 (0.11–6.73) 0.870
Previous regimen:
 2NRTI + bPI Ref   Ref  
 2NRTI + NNRTI 1.09 (0.65–1.81) 0.754 1.13 (0.66–1.93) 0.662
 2NRTI + InSTI 1.87 (1.21–2.90) 0.005 2.16 (1.30–3.60) 0.003
 Two-drug regimen 1.15 (0.79–1.67) 0.466 0.64 (0.37–1.10) 0.103
 Other 1.43 (0.79–2.59) 0.233 0.84 (0.41–1.71) 0.631
Switch from TDF-containing regimen 0.72 (0.54–0.95) 0.019 0.59 (0.39–0.88) 0.010
Reasons for switch to dual regimen:
 Simplification Ref   Ref  
 Dyslipidemia 0.71 (0.41–1.21) 0.207 0.74 (0.40–1.36) 0.332
 GI toxicity 1.04 (0.42–2.56) 0.929 1.12 (0.43–2.87) 0.820
 Liver toxicity 2.18 (1.14–4.16) 0.019 1.50 (0.71–3.17) 0.286
 Renal toxicity 1.17 (0.76–1.78) 0.475 1.14 (0.73–1.80) 0.565
 Bone toxicity 1.45 (0.60–3.62) 0.405 1.12 (0.3–2.91) 0.813
 CNS toxicity 1.21 (0.17–8.71) 0.849 1.94 (0.25–14.87) 0.524
 Other toxicity 2.98 (1.83–4.84) < 0.001 2.16 (1.27–3.70) 0.005
 DDI 2.24 (0.71–7.09) 0.169 1.82 (0.54–6.12) 0.330
 Other 1.37 (0.84–2.25) 0.207 1.25 (0.74–2.13) 0.408
Time on previous regimen (per 1 year more) 0.98 (0.92–1.04) 0.547 0.92 (0.85–0.99) 0.021
eGFR at baseline (per 10 mL/min/1.73 m more) 1.06 (1.00–1.11) 0.039 1.05 (0.99–1.11) 0.102
Total cholesterol at baseline (per 10 mg/dL more) 1.03 (1.00–1.06) 0.058 1.04 (1.01–1.07) 0.012
Years on antiretroviral therapy 1.01 (0.99–1.03) 0.208 1.01 (0.99–1.04) 0.330
Study period:
 2008–2013 Ref   Ref  
 2013–2014 2.04 (1.44–2.87) < 0.001 1.98 (1.37–2.88) < 0.001
 2014–2015 2.25 (1.47–3.43) < 0.001 4.88 (3.00–7.94) < 0.001
 2015–2017 2.18 (1.20–3.97) < 0.001 8.45 (4.12–17.31) < 0.001
Study treatment with Dolutegravir (versus bPIs) 0.50 (0.31–0.80) 0.004 0.15 (0.08–0.28) < 0.001
  1. Note: bPI boosted protease inhibitor, TDF tenofovir, GI gastrointestinal, CNS central nervous system, DDI drug-drug interaction, eGFR estimated glomerular filtration rate
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us